ERBB2 and triple-negative breast carcinoma: NAT is commonly used in patients with inoperable disease, as well as in those with invasive and high-risk breast cancer, such as stage II to III human epidermal growth factor receptor-2 (HER2) positive (HER2+) and triple-negative breast cancer (TNBC)9.